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40-word summary  
In this large longitudinal cohort analysis the incidence of chronic elevated ALT in HIV-
infected persons was 3.9 cases per 100 person-years. Significant predictors were 
increased body mass index, high alcohol use and prolonged exposure to stavudine 
and zidovudine. 
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ABSTRACT (247 words)  
Background: Chronic liver disease in HIV-infected patients is mostly due to hepatitis 
virus co-infections. Other reasons for chronic alanine aminotransferase (ALT) 
elevation are more difficult to diagnose. 
Methods: We studied the incidence of and risk factors for chronic ALT elevation 
(>upper limit of normal at >2 consecutive semi-annual visits) in participants of the 
Swiss HIV Cohort Study without HBV/HCV infections, seen between 2002-2008. 
Poisson regression analysis was used. 
Results: 2365 participants were followed for 9972 person-years (median age 38 yrs; 
66% male; median CD4 cells 426/μL; 56% on antiretroviral therapy [ART]). 385 
(16%) participants developed chronic elevated ALT (incidence 3.9/100 pyrs [95% CI 
3.5-4.3]). In multivariable analysis chronic elevated ALT was associated with HIV1-
RNA >100’000 copies/ml (incidence rate ratio, IRR, 2.23 [1.45-3.43]), increased body 
mass index (BMI 25-29.9, 1.56 [1.24-1.96]; BMI ≥30, 1.70 [1.16-2.51]), severe 
alcohol use (1.83 [1.19-2.80]), exposure to stavudine (IRR per year exposure, 1.12 
[1.07-1.17]) and zidovudine (1.04 [1.00-1.08]). Associations with cumulative exposure 
to combination ART, nucleoside reverse transcriptase inhibitors and unboosted 
protease inhibitors did not remain significant after adjustment for exposure to 
stavudine. Black ethnicity was inversely correlated (0.52 [0.33-0.82]). Treatment 
outcome and mortality did not differ between groups with and without ALT elevation.  
Conclusions: Among patients without hepatitis virus co-infections, the incidence of 
chronic ALT elevation was 3.9/100 pyrs, associated with high HIV1-RNA levels, 
increased BMI, severe alcohol use and prolonged stavudine and zidovudine 
exposure. Long-term follow-up is needed to assess whether chronic ALT elevation 
will result in increased morbidity or mortality. 
Revision CID MS 58306 4 of 25 
INTRODUCTION 
HIV-associated morbidity and mortality have decreased dramatically and 
continuously since the introduction of combination antiretroviral therapy (cART) [1-3]. 
Due to improved life expectancy, non-AIDS-defining diseases and drug-related 
toxicities have emerged as a key issue in the management of these patients. Liver-
related death is the most frequent cause of non-AIDS-related death [4]. The main 
causes of hepatopathy in HIV-infected persons are hepatitis C and B infections.  
Patients with HIV infection frequently have elevated liver function tests [5]. The 
cause and their clinical significance, particularly in absence of chronic viral hepatitis, 
often are unclear and make its assessment and management difficult. Several 
studies evaluated liver disease in patients with hepatitis C and B co-infections and 
most examinations have focused on severe liver enzyme elevations (defined as 3 to 
≥5x the upper limit of normal) [6-8]. However, the majority of patients only have mild 
to moderate increased liver enzymes. A recently published study examined liver 
biopsies in HIV-infected patients on ART with unexplained chronic elevated 
transaminases and found a high rate of histological abnormalities: 22/30 (73%) 
patients had either liver fibrosis and/or steatosis [9]. These results emphasize the 
importance of chronic elevated ALT. 
Two cross-sectional studies investigated predictors of liver enzyme elevation in 
HIV-infected patients without hepatitis C and B. However, the first study excluded 
patients with risk factors or evidence for non-alcoholic fatty liver disease and alcohol 
abuse [10]. The second study used only a single elevated alanine aminotransferase 
(ALT) value which is subjected to the high intraindividual variability of liver tests. 
Furthermore it is not clear whether ALT values were collected concurrent with clinical 
events or per protocol [11].  
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Given the lack of data regarding elevated ALT among HIV-positive patients 
without chronic viral hepatitis, we studied the incidence of and risk factors for chronic 
ALT elevation as a sign for chronic liver disease in a large prospective longitudinal 
multicenter cohort.  
 
METHODS 
Study Population 
The Swiss HIV Cohort study (SHCS) is an ongoing, prospective cohort study that 
was established in 1988 and that continuously enrolls and observes HIV-infected 
individuals aged ≥16 years at 5 university outpatient clinics, 2 large cantonal 
hospitals, affiliated regional hospitals, and private practices [12]. Information and 
laboratory values including liver enzymes are collected according to defined criteria 
at registration and follow-up visits every 6 months. The study was approved by local 
ethical review boards, and written informed consent was obtained from all 
participants.  
For this analysis, we included SHCS participants without hepatitis B and C 
infection and at least 3 consecutive semiannual visits with ALT determinations seen 
after 01.01.2002, the date when ALT values were regularly collected in the SHCS. 
The last follow-up visit was in December 2008. Patients with prevalent elevated ALT 
at time of the baseline visit were excluded. Baseline visit was defined as the first visit 
after 01.01.2002.  
 
Definitions 
Chronic ALT elevation was defined as ALT greater than the upper limit of normal at 2 
or more consecutive semiannual visits. HCV infection was defined as present in 
patients who were seropositive for HCV or who had test results positive for HCV 
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RNA. HBV infection was defined as present in patients who were positive for 
hepatitis B surface antigen or hepatitis B e antigen or hepatitis B core antibodies or 
who had detectable HBV DNA during the study period. Body mass index (BMI) was 
stratified into <18.5 (underweight), 18.5 – 24.9 (normal), 25 – 29.9 (overweight) and 
≥30 (obese) [13]. Central obesity was defined according to the new worldwide 
definition [14] with sex- and ethnicity-specific waist circumference cut-off values. 
Hypercholesterolemia and hypertriglyceridemia were defined as present in patients 
with total cholesterol >6.5 mmol/L and triglycerides >1.7 mmol/L, respectively. 
Diabetes mellitus was diagnosed according to the criteria of the Expert Committee on 
the Diagnosis and Classification of Diabetes Mellitus [15], with confirmed plasma 
glucose level cut–off values of >7.0 mmol/L (fasting) and >11.1 mmol/L (nonfasting). 
Elevated blood pressure was defined as present in patients with diastolic blood 
pressure ≥85 mmHg or systolic blood pressure ≥130 mmHg. Smoking status was 
stratified into never, former and current smoking. Alcohol use was stratified into 
severe use (female >40g/d, male >60g/d), moderate (female 20-40 g/d, male 40-60 
g/d) and light use (female <20 g/d, male <40 g/d) according to the WHO definition.  
 
Statistical Analysis 
We defined the incidence of chronic ALT elevation as the number of cases of chronic 
ALT elevation divided by the total number of person-years of follow-up (PYFU). 
Associations between incident chronic ALT elevation and demographic, clinical, 
anthropometric and drug-related covariables were analyzed in univariable and 
multivariable Poisson regression models. Fixed covariables were sex, ethnicity, 
mode of HIV acquisition and HIV CDC disease stage. For alcohol consumption, we 
used the highest consumption ever measured, even when it was reported by patients 
after development of chronic elevation of ALT, assuming that drinking habits remain 
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steady. Time-updated covariables were age, smoking status, BMI, central obesity, 
lipodystrophy, hypercholesterolemia, hypertriglyceridemia, diabetes mellitus, arterial 
hypertension, CD4 cell count, HIV-1 RNA and continuous and categorical years of 
exposure of cART, the different drug classes (nucleoside reverse transcriptase 
inhibitors [NRTI], protease inhibitors [PI] and non-nucleoside reverse transcriptase 
inhibitors [NNRTI]) and individual drugs. We focused on cumulative drug exposure 
and did not analyze current drug exposure. The endpoint of chronic ALT elevation is 
not suitable to detect acute effects of current drug exposure. In patients with an acute 
hepatotoxicity, the suspected drugs will be changed immediately to a less toxic 
regimen and persistent ALT elevation may be attributed to the new treatment, 
causing reverse causality problems [16]. We first build a multivariable model with 
demographic, clinical and anthropometric covariables including alcohol consumption. 
Next, we included cumulative exposure to the different drug classes and individual 
drugs. To disentangle the strong association with stavudine from the other drugs, we 
repeated the multivariable models with inclusion of stavudine exposure. We did not 
formally check for interactions due to the high number of potential combinations but 
checked for effect modifications during the model building process. Characteristics of 
different patient groups were compared using Chi-square tests or Wilcoxon rank-sum 
tests; for mortality Kaplan-Meier estimates and log-rank test were used. All analyses 
were performed using Stata software (version 10.1). 
 
RESULTS  
Patient characteristics 
Of 8435 SHCS participants seen between 01.01.2002 and 31.12.2007, 3255 (39%) 
were HBV and HCV negative. Of these, we excluded 760 with less than 3 follow-up 
visits, gaps in follow-up or missing data. 130 (5%) were excluded due to preexisting 
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elevated ALT at time before or at time of baseline visit (these patients were 
significantly longer exposed to ART compared to patients without prevalent elevated 
ALT, particularly to stavudine and zidovudine; data not shown). The present study is 
thus based on 2365 HIV-infected individuals with normal ALT values at baseline visit 
(Figure 1). 
Baseline characteristics of patients with and without incident chronic elevation of 
ALT during follow-up are summarized in Table 1. The proportion of men was 66%. 
Median age was 38 years. 84% were Caucasian. Baseline and nadir (i.e., lowest 
ever) CD4 lymphocyte counts were 426 and 249 cells/μl, respectively. Median 
duration of antiretroviral therapy was 1.2 years; 34% were treatment naive, 10% had 
interrupted ART and 56% were on treatment. HIV-1 RNA in ART treated patients was 
in 70% below level of detection. Several of the baseline variables were associated 
with the development of chronic ALT elevation. 
During the follow-up period, 385 patients (16%) developed chronic elevated ALT 
over 9972 person-years of follow-up (PYFU), resulting in an incidence of 3.9 cases 
per 100 PYFU (95% C.I. 3.5 - 4.3). The incidence was significantly decreasing over 
time with an IRR of 0.84 (0.79-0.88) per year: 2002-2003 the incidence was 5.6 
cases per 100 PYFU (4.7-6.8), 2004-2005 4.5 cases per 100 PYFU (3.8-5.3) and 
2006-2008 2.8 cases per 100 PYFU (2.3-3.3).  
 
Univariable and multivariable models 
The results of the uni- and multivariable Poisson regression analyses are displayed 
in Table 2. Black ethnicity and CD4 category 200-500 cells/μl compared to >500 
cells/μl were negative predictors for chronic elevated ALT. HIV-1 RNA >100’000 
copies/ml was a strong positive predictor. There was no effect of age, sex, HIV 
transmission category, CDC stage C, nadir CD4 cell count, smoking and medications 
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other than ART, except lipid lowering drugs (see below), on the incidence of chronic 
elevated ALT. Results of the univariable and multivariable model were identical.  
 
Association of metabolic parameters and chronic elevated ALT 
In univariable and multivariable analysis increased BMI was significantly associated 
with chronic elevated ALT (BMI 25-29.9 kg/m2, IRR 1.56, 1.24-1.96; BMI ≥30 kg/m2, 
1.70, 1.16-2.51). Other risk factors for non-alcoholic fatty liver disease [17, 18], 
including central obesity (IRR 1.66, 95% CI 1.36-2.03), lipoatrophy (1.50, 1.19-1.90), 
lipohypertrophy (1.79, 1.43-2.23), hypercholesterolemia (1.63, 1.25-2.12), 
hypertrigliceridemia (1.75, 1.43-2.15), use of lipid lowering drugs (1.48, 1.11-1.98) 
and arterial hypertension (1.27, 1.04-1.55) were also predictors for chronic elevated 
ALT in the univariable analyses, but these variables were not included in the 
multivariable model, because of collinearity or the same causal pathway. Diabetes 
mellitus was not significant in the univariable analysis (IRR 1.05, 0.59-1.87). 
 
Association of alcohol use and chronic elevated ALT  
We analyzed the contribution of severe, moderate and light alcohol use to the 
development of elevated ALT in univariable and multivariable models. Only severe 
alcohol use was significantly associated with the incidence of elevated ALT, 
moderate and light use was not. 
 
Association of antiretroviral treatment and chronic elevated ALT  
Associations of antiretroviral treatment and chronic elevated ALT are shown in Table 
3 and Figure 2. Cumulative exposure as continuous variable to cART, NRTI and 
unboosted PI increased the risk of developing chronic elevated ALT in the univariable 
and multivariable model. Among individual antiretroviral drugs, the strongest 
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relationship with chronic elevated ALT was with exposure to stavudine (IRR per year 
of exposure 1.12, 1.07-1.17; p<0.001). There was also a significant effect of 
didanosine, lamivudine, nelfinavir and nevirapine. However, after adjustment for 
stavudine exposure none of the antiretroviral classes or individual drugs remained 
significant. After adjusting to stavudine, exposure to zidovudine was associated with 
an increased risk of chronic ALT elevation, whereas exposure to emtricitabine was 
conversely associated (see Table 3). When we stratified cumulative exposure into 
categorical variables (never, ≤2 years, 2-5 years, >5 years) cART, NRTI and 
unboosted PI exposure >2 years were a risk factor for chronic elevated ALT, but did 
not remain predictive after adjustment for stavudine exposure. NNRTI exposure <5 
years showed an association with elevated ALT (Figure 2). Nevirapine as a 
categorical variable was a risk factor for chronic ALT elevation with short-term use 
(<2 years) with and without adjustment for stavudine exposure (data not shown). 
 
Sensitivity analyses 
In separate models we analyzed ≥3 consecutive elevated ALT values instead of ≥2 at 
semiannual visits. The incidence for 3 consecutive elevated ALT values was 2.1 per 
100 PYFU (95% CI 1.9 - 2.4) in 228 patients followed-up for 10,628 person-years. 
Univariable and multivariable evaluations with this modified definition yielded 
consistent results.  
 
Clinical Outcome 
Four (1.0%) of the patients with elevated ALT versus 30 (1.5%) of the patients 
without elevated ALT died. 5-year mortality between patients with and without 
development of chronic elevated ALT did not differ significantly: 0.3% (0.04%-2.2%) 
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versus 1.6% (1.1%-2.5%), respectively (p=0.14). Reasons for death in the elevated 
ALT group were suicide, myocardial infarction, bladder cancer and acute peritonitis.  
At last visit, 86.0% of the patients with elevated ALT vs. 78.8% of those with 
normal ALT were on ART, 9.6% vs. 10.8% had interrupted ART and 4.4% vs. 10.4 % 
were ART-naïve (p=0.001). For those who were on ART, HIV1-viral load was 
suppressed equally (87% vs. 85%) and the CD4 cell count was 593 cells/μl (430-767) 
vs. 525 cells/μl (384-714). Number of treatment changes per year, including 
treatment switches and interruptions, did not differ between the two groups (data not 
shown).  
 
DISCUSSION 
In this large longitudinal cohort analysis the incidence of chronic elevated ALT, i.e. 
elevation for 6 or more months, was 3.9 cases per 100 PYFU. In adjusted analyses, 
increased BMI, high alcohol use and prolonged exposure to stavudine and 
zidovudine were associated with chronic ALT elevation.  
In contrast to cross-sectional analyses in which the temporal sequence of 
exposure and outcome is often not ascertained, the longitudinal design chosen for 
our study should allow for a more precise determination of predictors. To our 
knowledge, there are no data available for the incidence of ALT elevation in an HIV-
infected population without chronic viral hepatitis. However, several studies reported 
on the prevalence of elevated ALT in the general population and in HIV-infected 
persons. The large NHANES III study, representing a civilian noninstitutionalized 
population in the United States, found a prevalence of 13.5% in HCV and HBV 
negative individuals [19]. A German cohort study of orthopedic surgery patients 
without chronic viral hepatitis noted a prevalence of 11.3% [20] and in HIV-infected 
persons without viral hepatitis the prevalence was in the same range with 15% [11]. 
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These figures are in accordance with our study with a prevalence of 13.2% in a 
single ALT measurement at baseline (data not shown).  
Our results confirm that the main causes of chronic liver disease in HIV-infected 
patients without hepatitis B and C co-infections are alcohol consumption, non-
alcoholic fatty liver disease (NAFLD) and antiretroviral drugs.  
Several mechanisms of antiretroviral drugs resulting in liver enzyme elevation 
have been postulated: mitochondrial toxicity related to NRTIs, hypersensitivity, 
primarily caused by nevirapine and metabolic injury, mainly associated to PIs through 
their effects on metabolic factors [21]. In our analysis the strongest relationship with 
the development of chronic elevated ALT was with exposure to stavudine. 
Furthermore, with decreasing stavudine use over time, the incidence of ALT 
elevation was significantly decreasing during the observation period. The association 
with this dideoxynucleoside analogues does not surprise, as it is a strong inhibitor of 
mitochondrial DNA synthesis resulting in a high mitochondrial toxicity [22]. Stavudine 
has been implicated in the development of hepatic steatosis [23, 24]. The other 
dideoxynucleoside analogues, didanosine, has recently been postulated as a cause 
for noncirrhotic portal hypertension [25] [26], but in our study showed only a trend 
with chronic elevated ALT. Nevirapine, known to cause early acute hepatitis 
produced by a hypersensitivity mechanism [27], was associated with elevated ALT as 
a categorical variable during the first 2 years of exposition (data not shown). 
It was to be expected that the traditional risk factors for non-alcoholic fatty liver 
disease, namely increased BMI, central obesity, lipodystrophy and dyslipidemia, as 
well as severe alcohol consumption were associated with the development of 
elevated ALT, a surrogate marker for hepatic steatosis [28]. Hepatic steatosis is 
common in HIV-infected persons with metabolic abnormalities with [23, 29] and 
without hepatitis C co-infection [30, 31] [9]. Besides the metabolic aberrations and 
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severe alcohol use ART-related mitochondrial toxicity might contribute to hepatic 
steatosis, but hepatic steatosis might also be a predisposing factor for antiretroviral 
hepatotoxicity [32]. This needs to be further evaluated. 
Our finding of black ethnicity as a negative predictor for ALT elevation is in 
agreement with other investigations which found an inverse association of black 
ethnicity and NAFLD in the general population [33] and in HIV-infected patients [24, 
31, 34]. Yet, it is unknown whether ethnic or genetic factors may play a role in 
protecting from hepatopathy.  
Similarly with two other reports, a high HIV-1 viral load was an independent risk 
factor for the development of chronic elevated ALT [11], respectively steatosis [29]. 
The mechanisms associated with this observation are possibly due to immune 
activating and pro-apoptotic effects of HIV on hepatocytes, demonstrated in several 
studies (reviewed in [35]). 
The NHANES III study found a strong association of liver related mortality and 
elevated ALT in a general population without chronic viral hepatitis [19]. In addition, 
elevated ALT in HIV-infected patients reported as adverse event to antiretrovirals 
was associated with a higher mortality independently from chronic viral hepatitis co-
infections [36]. This is in contrast to our data, which did not show a higher mortality, 
presumably because of a relatively short observation period.  
The strengths of this study are the large number of patient-years with 
prospectively collected anthropometric, laboratory and clinical data including 
assessment of alcohol use. ALT determination was according to study protocol and 
not triggered by symptoms or clinical events. Limitations include the use of a 
laboratory surrogate marker, i.e. elevated ALT, as a sign for hepatopathy instead of 
liver tissue examination. However, liver biopsies were not feasible in this large 
epidemiologic study, and elevated ALT is considered a highly specific indicator for 
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liver injury which is the most commonly used marker for chronic liver disease. 
Regarding the high intraindividual variability of liver tests [37], we used two 
consecutive elevated ALT-values over a time period of 6 months. Because we 
excluded patients with preexisting elevated ALT at baseline (these patients were 
longer exposed to ART, particularly to NRTIs) the incidence of chronic ALT elevation 
in patients on ART may be underestimated. We did not consider hemochromatosis, 
autoimmune hepatitis or infections other than HCV and HBV such as hepatitis A, 
cytomegalovirus or Epstein-Barr virus infections, but as they are very infrequent 
causes of chronic elevation of ALT among HIV-infected persons, no significant 
influence on the analysis would be expected. Finally, results from cohort analyses 
need to be interpreted with caution because of the potential for unmeasured 
confounding.  
In summary, we evaluated the incidence of and factors associated with chronic 
elevated ALT in HIV-infected patients without hepatitis B and C co-infections. Chronic 
ALT elevation is frequent in this population. Besides those factors classically 
recognized as predisposing to hepatic steatosis in HIV-negative individuals, such as 
being overweight and elevated alcohol consumption, high HIV1-RNA levels and 
exposure to stavudine and zidovudine were associated with chronic elevated ALT. 
Our findings may have clinical implications given the fact that several studies suggest 
an association of chronic elevated ALT and an increased mortality [19][36], 
respectively a high rate of severe histological abnormalities [9]: early recognition and 
management of metabolic factors (overweight, dyslipidemia), prevention or treatment 
of severe alcohol use, early initiation of cART if HIV1-RNA is high, and avoiding 
stavudine and zidovudine in case of chronically elevated ALT. Long-term follow-up is 
needed to assess whether chronic ALT elevation will result in increased morbidity or 
mortality.
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Table 1: Baseline characteristics of 2365 persons with and without incident chronic elevation of 
alanine aminotransferase (ALT) during follow-up.  
 
 All subjects 
Chronic 
elevation of 
ALT during 
follow-up 
No chronic 
elevation of 
ALT during 
follow-up 
P  
value 
No. of patients 2365 385 1980  
Sex female 800 (34%) 138 (36%) 662 (33%) 0.4 
 male 1565 (66%) 247 (64%) 1318 (67%)  
Age, years median (IQR) 38 (33-45) 40 (35-47) 38 (33-45) <0. 001 
Race white 1989 (84%) 337 (88%) 1652 (83%) 
 black 234 (10%) 23 (6%) 211 (11%) 
 hispanic 62 (3%) 12 (3%) 50 (3%) 
 asian 77 (3%) 12 (3%) 65 (3%) 
 other 3 (0.1%) 1 (0.3%) 2 (0.1%) 
0.06 
Mode of HIV infection            heterosexual 1242 (53%) 217 (56%) 1025 (52%) 
 homosexual 982 (42%) 150 (39%) 832 (42%) 
 injecting drug use 26 (1%) 6 (2%) 20 (1%) 
0.1 
 other 115 (5%) 12 (3%) 103 (5%)  
Date of HIV 
diagnosis 
median 5/2000 
(4/1996-
5/2004) 
9/1997 
(5/1994-
1/2001) 
3/2001 
(9/1996-
10/2004) 
<0. 001 
median (IQR) 426 (269-614) 492 (313-695) 420 (264-597) <0.001 Baseline CD4 
cells/µL 0-199 340 (14%) 36 (9%) 304 (15%)  
 200-499 1105 (47%) 159 (41%) 946 (48%)  
 500+ 917 (39%) 189 (49%) 728 (37%)  
Nadir CD4 cells/µL median (IQR) 249 (119-403) 216 (99-361) 256 (124-409) 0.002 
HIV-1 RNA in ART-naïve     median (IQR) 
patients copies/mL log     
4.5 (3.9-5.1) 4.5 (4.0-5.0) 4.5 (3.9-5.1) 0.9 
HIV-1 RNA in ART treated patients 
< level of detection         no. (%) 
1649 (70%) 239 (62%) 1410 (71%) <0. 001 
Peak HIV-1 RNA                  median (IQR) 
copies/ml log 
4.9 (4.1-5.4) 4.9 (4.3-5.3) 4.9 (4.1-5.4) 1.0 
Previous clinical AIDS                  no. (%) 402 (17%) 81 (21%) 321 (16%) 0.02 
BMI, kg/m2 median (IQR) 23 (21-25) 24 (22-26) 23 (21-25) <0. 001 
<18.5 98 (4%) 13(3%) 85 (4%)  
18.5-24.9 1587 (68%) 226 (59%) 1361 (70%)  
25-29.9 539 (23%) 119 (31%) 420 (21%)  
30 113 (5%) 22 (6%) 91 (5%)  
Central obesity a         no. (%) 651 (28%) 146 (38%) 505 (26%) <0. 001 
Lipodystrophy, no. (%) Atrophy 310 (13%) 76 (20%) 234 (12%) <0. 001 
 Fat accumulation 316 (13%) 88 (23%) 228 (12%) <0. 001 
Diabetes mellitus       no. (%) 52 (2%) 6 (2%) 46 (2%) 0.3 
Total cholesterol b, mmol/L  median (IQR) 4.9 (4.2-5.8) 5.3 (4.5-6.4) 4.8 (4.1-5.7) <0. 001 
 >6.5, no. (%) 275 (12%) 78 (21%) 197 (10%)  
HDL cholesterol b, mmol/L     median(IQR) 1.2 (1.0-5.8) 1.2 (1.0-6.4) 1.2 (1.0-5.7) 0.8 
<1.0 (male), <1.3 (female), no. (%) 885 (39%) 144 (39%) 741 (39%)  
Triglycerides b, mmol/L         median (IQR) 1.6 (1.0-2.6) 2.0 (1.3-3.6) 1.5 (1.0-2.4) <0. 001 
 >1.7, no. (%) 1051 (46%) 215 (58%) 836 (44%)  
Arterial hypertension c       no. (%)   1042 (44%) 192 (50%) 850 (43%) 0.01 
Smoking status d, no. (%)                  never 1274 (54%) 210 (55%) 1064 (54%) 0.03 
 former 103 (4%) 26 (7%) 77 (4%)  
 current 977 (42%) 149 (39%) 828 (42%)  
Active IDU d              no. (%) 6 (0.3%) 0 (0%) 6 (0.3%) 0.3 
Alcohol consumption e  g/d       mean (IQR) 14.4 (6-20) 18.4 (6-20) 13.7 (6-20) 0.4 
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 All subjects 
Chronic 
elevation of 
ALT during 
follow-up 
No chronic 
elevation of 
ALT during 
follow-up 
P  
value 
Alcohol consumption e, 
no. (%) 
None
Light
Moderate
severe
646 (27%) 
1393 (59%) 
220 (9%) 
106 (4%) 
108 (28%) 
206 (54%) 
42 (11%) 
29 (8%) 
538 (27%) 
1187 (60%) 
178 (9%) 
77 (4%) 
0.004 
Antiretroviral therapy                          naive 812 (34%) 74 (19%) 738 (37%) <0. 001 
 currently interrupted 228 (10%) 37 (10%) 191 (10%)  
 on treatment 1325 (56%) 274 (71%) 1051 (53%)  
ART duration, years Median (IQR) 1.2 (0-5.0) 3.6 (0.4-5.7) 0.6 (0-4.8) <0. 001 
 
 
Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; HDL, high density lipoprotein; 
IDU, intravenous drug use; 
 
a For central obesity definition, see “statistical analysis”. 
b Normal values: total cholesterol <6.5 mmol/L; HDL cholesterol >1mmol/L for male, >1.3mmol/L for 
female; triglycerides <1.7mmol/L 
c For arterial hypertension definition, see “statistical analysis”.  
d Smoking and active IDU: in the 6 months prior to baseline visit  
e for alcohol consumption we used the highest consumption ever measured. 
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Table 2: Univariable and multivariable Poisson regression of demographic, clinical and anthropometric 
covariables potentially affecting the risk of developing chronic elevation of alanine aminotransferase 
(ALT) based upon 2365 individuals with 385 events followed for 9972 person-years.  
 
 
 IR 
 per 1000 PYFU 
(95% C.I.) 
IRR 
univariable models 
(95% C.I.)  
IRR  
multivariable model * 
(95%C.I) 
Sex female 40 (33-47) 1 1 
 male 38 (34-43) 0.96 (0.78-1.19) 0.84 (0.63-1.11) 
Age, per 10 years  1.06 (0.97-1.17) 1.0 (0.90-1.11) 
Race white 40 (36-44) 1 1 
 black 24 (16-36) 0.60 (0.39-0.91) 0.52 (0.33-0.82) 
 hispanic 50 (28-88) 1.25 (0.70-2.23) 1.14 (0.64-2.06) 
 asian 42 (24-73) 1.05 (0.59-1.86) 1.11 (0.62-2.01) 
 unknown 67 (9-473) 1.67 (0.23-11.9) 2.22 (0.31-16.0) 
heterosexual 40 (35-46) 1 1 
homosexual 38 (32-44) 0.94 (0.76-1.15) 1.03 (0.79-1.36) 
IDU 47 (21-104) 1.16 (0.52-2.61) 1.38 (0.61-3.14) 
Mode of HIV 
infection 
other 25 (14-44) 0.62 (0.35-1.11) 0.62 (0.35-1.12) 
CD4 cells/µL 0-199 34 (22-53) 0.80 (0.49-1.27) 0.61 (0.37-1.01) 
 200-499 35 (30-41) 0.81 (0.66-0.99) 0.73 (0.58-0.91) 
 500+ 43 (38-49) 1 1 
Nadir CD4 cells/µL        0-199 41 (36-47) 1.01 (0.70-1.45) 1.33 (0.89-1.99) 
200-499 36 (30-42) 0.88 (0.61-1.26) 1.02 (0.70-1.50) 
500+ 41 (29-57) 1 1 
HIV-1 RNA                0-10'000 37 (33-42) 1 1 
copies/ml       10'000-100'000 39 (29-52) 1.05 (0.77-1.43) 1.22 (0.88-1.70) 
                                 100'000 69 (46-103) 1.85 (1.22-2.80) 2.23 (1.45-3.43) 
BMI                                <18.5 22 (12-41) 0.66 (0.35-1.24) 0.64 (0.34-1.21) 
18.5-24.9 34 (30-38) 1 1 
25-29.9 51 (43-61) 1.52 (1.22-1.89) 1.56 (1.24-1.96) 
30 57 (40-81) 1.69 (1.16-2.45) 1.70 (1.16-2.51) 
Smoking status              never  40 (34-47) 1 1 
former 47 (39-57) 1.17 (0.91-1.50) 1.04 (0.79-1.38) 
current 33 (28-39) 0.81 (0.64-1.02) 0.79 (0.62-1.00) 
Alcohol consumption     None  40 (33-48) 1 1 
Light 35 (31-40) 0.89 (0.70-1.12) 0.91 (0.71-1.16) 
Moderate 44 (32-59) 1.10 (0.77-1.57) 1.13 (0.78-1.62) 
Severe 67 (46-96) 1.68 (1.12-2.53) 1.83 (1.19-2.80) 
 
Abbreviations: BMI, body mass index; IDU, intravenous drug use; IR, incidence rate; IRR, incidence 
rate ration; PYFU, person-years of follow-up 
 
* Adjusted for all variables listed. 
 
Age, CD4 cells, nadir CD4, HIV-1 RNA, BMI and smoking status were analyzed as time-updated 
covariables. For alcohol consumption we used the highest ever measured. 
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Table 3: Multivariable Poisson regression of cART, different ART classes and single drugs (time-updated cumulative exposure) potentially affecting the risk of 
developing chronic elevated ALT.  
 
Antiretroviral therapy or 
individual antiretroviral 
drugs per year exposure 
IRR from univariable 
models (95% C.I.) 
P value IRR from multivariable 
models a (95% C.I.)  
P value IRR from multivariable 
models including 
stavudine exposure b 
(95% C.I.) 
P value 
cART 1.04 (1.01-1.07) 0.015 1.05 (1.01-1.08) 0.015 1.00 (0.96-1.04) 0.9 
NRTI 1.05 (1.02-1.08) <0.001 1.06 (1.03-1.09) <0.001 1.03 (0.99-1.07) 0.1 
Unbooosted PI  1.06 (1.02-1.11) 0.002 1.07 (1.02-1.11) 0.003 1.03 (0.98-1.07) 0.3 
Boosted PI  1.02 (0.97-1.07) 0.5 1.01 (0.96-1.07) 0.6 0.98 (0.93-1.04) 0.5 
NNRTI 1.03 (0.98-1.08) 0.2 1.03 (0.98-1.08) 0.2 1.01 (0.96-1.06) 0.6 
NRTIs       
Stavudine 1.11 (1.07-1.16) <0.001 1.12 (1.07-1.17) <0.001 - - 
Zidovudine 1.02 (0.99-1.05) 0.3 1.02 (0.98-1.06) 0.3 1.04 (1.00-1.08) 0.028 
Didanosine 1.06 (1.00-1.12) 0.045 1.07 (1.01-1.13) 0.024 1.03 (0.97-1.09) 0.4 
Lamivudine 1.04 (1.01-1.07) 0.019 1.04 (1.00-1.08) 0.039 1.02 (0.98-1.05) 0.4 
Abacavir 0.10 (0.94-1.05) 0.9 0.99 (0.93-1.04) 0.7 0.98 (0.93-1.04) 0.5 
Emtricitabine 0.44 (0.25-0.77) 0.004 0.45 (0.25-0.78) 0.005 0.47 (0.27-0.82) 0.008 
Tenofovir 0.96 (0.86-1.06) 0.4 0.96 (0.86-1.07) 0.5 0.93 (0.84-1.04) 0.2 
PIs       
Nelfinavir 1.07 (1.02-1.12) 0.006 1.07 (1.02-1.12) 0.007 1.03 (0.98-1.09) 0.2 
Lopinavir 1.02 (0.95-1.11) 0.6 1.02 (0.94-1.11) 0.7 1.01 (0.93-1.10) 0.8 
Saquinavir 1.05 (0.97-1.13) 0.2 1.04 (0.96-1.12) 0.3 0.97 (0.89-1.05) 0.4 
Indinavir 1.05 (0.98-1.12) 0.2 1.03 (0.97-1.10) 0.3 1.00 (0.93-1.07) 1.0 
Atazanavir 0.91 (0.76-1.09) 0.3 0.89 (0.74-1.07) 0.2 0.87 (0.73-1.04) 0.1 
Ritonavir, full dose 0.98 (0.87-1.11) 0.7 0.98 (0.87-1.12) 0.8 0.95 (0.83-1.09) 0.5 
NNRTIs       
Efavirenz 0.99 (0.94-1.05) 0.8 0.99 (0.94-1.05) 0.8 0.98 (0.92-1.04) 0.5 
Nevirapine 1.10 (1.02-1.18) 0.012 1.10 (1.02-1.18) 0.013 1.07 (0.99-1.15) 0.07 
 
Abbreviations: cART, combination antiretroviral therapy; NRTI, nucleosid reverse transcriptase inhibitor; NNRTI non-nucleosid reverse transcriptase inhibitor; PI, 
protease inhibitor;  
 
a The different drugs were individually adjusted for the covariables listed in Table 2. 
b The different drugs were individually adjusted for the covariables listed in Table 2 and the cumulative exposure to stavudine per year
Revision CID MS 58306 21 of 25 
Figure 1:  Patient Flowchart  
 
Abbreviations: ALT, alanine aminotransferase; HBV, hepatitis B virus; HCV, hepatitis C virus;  
 
 
 
 
All patients seen between
01.01.2002 – 31.12.2007 
n= 8435 
HCV or HBV n= 5014
HCV or HBV status unknown
n= 166
Patients without HCV or HBV seen between
01.01.2002 – 31.12.2006
n= 3255
<3 visits with ALT determinations
n= 271
Gaps in follow-up >1year n= 375
Missing data n=114
ALT >norm at baseline n= 130
Patients selected for the study n= 2365
Patients not developing
chronic elevated ALT  
n= 1980
Patients developing
chronic elevated ALT  
n=385
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Figure 2: Incidence rate ratios (IRRs) for the development of new chronic elevation of  
alanine aminotransferase (ALT) based on 385 events among 2365 participants with 9972 person 
years of follow-up. Shown are associations with receipt of combination antiretroviral therapy (cART) 
and specific drug classes for 0 years, 2 years, 5 years and more than 5 years. Left panel: 
Multivariable models were individually adjusted for the variables listed in Table 2. Right panel: 
Multivariable models were individually adjusted for the variables listed in Table 2 and cumulative 
exposure to stavudine.   
 
Additionally adjusted for the 
cumulative exposure to stavudine
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